Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Steinert Disease”

217 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 217 results

Not applicableLooking for participantsNCT07385443
What this trial is testing

The Spanish National Registry for Myotonic Dystrophy Type 1

Who this might be right for
Myotonic Dystrophy 1DM1Myotonic Dystrophy Type 1+2 more
Fundació Institut Germans Trias i Pujol 3,000
Not applicableStudy completedNCT00622453
What this trial is testing

Arrhythmias in Myotonic Muscular Dystrophy

Who this might be right for
Muscular DystrophyArrhythmiaSudden Cardiac Death
Indiana University 448
Not applicableLooking for participantsNCT06272799
What this trial is testing

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 160
Testing effectiveness (Phase 2)Ended earlyNCT03190967
What this trial is testing

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Who this might be right for
Breast CancerBrain MetastasisBrain Cancer
National Cancer Institute (NCI) 12
Early research (Phase 1)Study completedNCT00052000
What this trial is testing

A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 29
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Not applicableStudy completedNCT04018820
What this trial is testing

Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1

Who this might be right for
Myotonic Dystrophy 1
Élise Duchesne 11
Large-scale testing (Phase 3)Active Not RecruitingNCT06265428
What this trial is testing

Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
DualityBio Inc. 228
Not applicableUnknownNCT03554590
What this trial is testing

DM1, Effects of Carbo-Counting on Glycemic Control

Who this might be right for
Type 1 Diabetes Mellitus
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 50
Not applicableStudy completedNCT05865483
What this trial is testing

Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)

Who this might be right for
Myotonic Dystrophy 1Dysphagia, Oropharyngeal
University College, London 177
Testing effectiveness (Phase 2)Study completedNCT01745965
What this trial is testing

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

Who this might be right for
Breast Cancer
West German Study Group 380
Testing effectiveness (Phase 2)Looking for participantsNCT06300307
What this trial is testing

Study of ATX-01 in Participants With DM1

Who this might be right for
Myotonic Dystrophy 1
ARTHEx Biotech S.L. 56
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Not applicableActive Not RecruitingNCT05072288
What this trial is testing

A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy

Who this might be right for
Myotonic Dystrophy Type 1 (DM1)
Université du Québec à Chicoutimi 40
Early research (Phase 1)Ended earlyNCT04042051
What this trial is testing

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer+1 more
Cancer Trials Ireland 2
Large-scale testing (Phase 3)Study completedNCT01702571
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 2,185
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Large-scale testing (Phase 3)Study completedNCT04624750
What this trial is testing

Open Label Study in Adolescents and Children With Myotonic Disorders

Who this might be right for
Myotonic Dystrophy
Lupin Ltd. 12
Not applicableEnrolling By InvitationNCT07072676
What this trial is testing

The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.

Who this might be right for
Inclusion Body MyositisMyotonic Dystrophy 1Myotonic Dystrophy 2+10 more
LMU Klinikum 30
Large-scale testing (Phase 3)Looking for participantsNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,600
Load More Results